Anttila Sami, Viikki Merja, Huuhka Kaija, Huuhka Martti, Huhtala Heini, Rontu Riikka, Lehtimäki Terho, Leinonen Esa
University of Tampere, Medical School, 33014 University of Tampere, Finland.
Neurosci Lett. 2009 Oct 16;464(1):43-6. doi: 10.1016/j.neulet.2009.08.018. Epub 2009 Aug 11.
The association of two tryptophan hydroxylase 2 (TPH2) polymorphisms and treatment response in electroconvulsive therapy (ECT) and the risk of depression was studied. The patient sample consisted of 119 subjects with treatment-resistant major depressive disorder who were treated with ECT. Treatment response was assessed by the Montgomery and Asberg Depression Rating Scale (MADRS) scores. Patients who had <8 scores in post-treatment MADRS were considered remitters; scores >15 indicated non-response. The polymorphisms studied (rs1386494 and rs1843809) were not associated with treatment response to ECT. However, TPH2 rs1386494 A/A genotype carrying patients had significantly higher MADRS scores before ECT than A/G+G/G genotype carriers (p<0.001). A/A genotype carriers also had a greater decline in MADRS scores than A/G+G/G genotype carriers during the course of ECT treatment (p=0.03). This polymorphism may be associated with the severity of treatment-resistant depression. ECT may able to counteract a putative genetically driven worse depressive phenotype.
研究了两种色氨酸羟化酶2（TPH2）多态性与电休克治疗（ECT）的治疗反应及抑郁症风险之间的关联。患者样本包括119例接受ECT治疗的难治性重度抑郁症患者。通过蒙哥马利-阿斯伯格抑郁评定量表（MADRS）评分评估治疗反应。治疗后MADRS评分<8分的患者被视为缓解者；评分>15分表明无反应。所研究的多态性（rs1386494和rs1843809）与ECT的治疗反应无关。然而，携带TPH2 rs1386494 A/A基因型的患者在ECT治疗前的MADRS评分显著高于A/G+G/G基因型携带者（p<0.001）。在ECT治疗过程中，A/A基因型携带者的MADRS评分下降幅度也大于A/G+G/G基因型携带者（p=0.03）。这种多态性可能与难治性抑郁症的严重程度有关。ECT可能能够抵消一种假定的由基因驱动的更严重的抑郁表型。
